サンプル依頼リスト カート
  • English
  • Korean
表紙：子宮筋腫治療薬の世界市場規模調査＆予測、薬剤クラス別、タイプ別、エンドユーザー別、地域別分析、2023-2030年
市場調査レポート
商品コード
1303578

子宮筋腫治療薬の世界市場規模調査＆予測、薬剤クラス別、タイプ別、エンドユーザー別、地域別分析、2023-2030年

Global Uterine Fibroid Treatment Drugs Market Size study & Forecast, By Drug Class, By Type, By End-user and Regional Analysis, 2023-2030
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
子宮筋腫治療薬の世界市場規模調査＆予測、薬剤クラス別、タイプ別、エンドユーザー別、地域別分析、2023-2030年
出版日: 2023年07月01日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

子宮筋腫治療薬の世界市場は、2022年に約18億米ドルと評価され、予測期間2023-2030年には10.2％以上の健全な成長率で成長すると予測されています。

子宮筋腫治療薬は、子宮筋腫を治療するために特別に開発されたもので、子宮筋腫は子宮内で成長する良性腫瘍です。これは、生殖年齢の女性の子宮に影響を及ぼす一般的な非がん性疾患です。子宮筋腫治療薬市場は、新製品の発売数の増加や子宮筋腫の有病率の上昇などの要因によって牽引されています。

これらの薬剤には、GnRHアゴニスト、黄体ホルモン放出IUD、SPRM、非ステロイド性抗炎症薬、トラネキサム酸などが含まれ、子宮筋腫の縮小、大量出血や疼痛などの症状の管理、またはその両方を目的としています。2022年6月、経口GnRH拮抗薬であるイセルティが、子宮平滑筋腫の中等度から重度の症状に対する治療薬としてEMAから承認されました。GnRH拮抗薬マイフェンブリーは、子宮筋腫に伴う大量出血の治療薬として米国FDAから認可されました。それとともに2021年5月、マイオバント・サイエンシズ社とファイザー社は、子宮筋腫に伴う大量出血の治療薬として特別に適応のあるマイフェンブリー（レルゴリックス）の米国FDA認可を取得しました。これらの新発売薬の有効性が市場の成長を生み出しています。さらに、子宮筋腫治療に対する女性の意識の高まりや、子宮筋腫の早期発見・治療に取り組むさまざまな政府も、市場に有利な機会を生み出す可能性があります。しかし、子宮筋腫治療薬の高コストが市場の成長を妨げています。

世界の子宮筋腫治療薬市場の調査で考慮された主要地域には、アジア太平洋、北米、欧州、ラテンアメリカ、中東＆アフリカが含まれます。北米は、子宮筋腫の有病率の上昇、子宮筋腫による妊娠合併症の症例の増加、新規治療オプションの承認により、2022年の市場を独占しました。アジア太平洋は、インドや中国といった人口の多い2つの国の存在により、予測期間中に最も急成長する地域と考えられています。世界企業は、同地域での治療法の開発・商業化のために現地企業と契約を結んでいます。

本調査の目的は、近年のさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面の両方を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

  • 市場スナップショット
  • 世界市場・セグメント別市場推計・予測、2020-2030年
  • 主要動向
  • 調査手法
  • 調査前提条件

第2章 子宮筋腫治療薬の世界市場定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 産業の進化
    • 調査範囲
  • 調査対象年
  • 通貨換算レート

第3章 子宮筋腫治療薬の世界市場力学

  • 子宮筋腫治療薬市場の影響分析（2020-2030年）
    • 市場促進要因
      • 新製品上市数の増加
      • 子宮筋腫の有病率の上昇
    • 市場の課題
      • 子宮筋腫治療薬の高コスト
    • 市場機会
      • 女性の子宮筋腫に対する意識の高まり
      • 子宮の早期発見と治療に対する政府の注力

第4章 子宮筋腫治療薬の世界市場産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォース影響分析
  • PEST分析
    • 政治
    • 経済
    • 社会
    • 技術
    • 環境
    • 法律
  • 主な投資機会
  • 主要成功戦略
  • COVID-19影響分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの結論・提言

第5章 子宮筋腫治療薬の世界市場：薬物クラス別

  • 市場スナップショット
  • 子宮筋腫治療薬の世界市場：薬物クラス別、実績 - ポテンシャル分析
  • 子宮筋腫治療薬の世界市場：薬物クラス別推定・予測（2020-2030年）
  • 子宮筋腫治療薬の世界市場、サブセグメント別分析
    • ゴナドトロピン放出ホルモン（GnRH）作動薬
    • ゴナドトロピン放出ホルモン（GnRH）拮抗薬
    • 黄体ホルモン放出子宮内避妊器具（IUD）＆避妊薬
    • 非ホルモン薬
    • その他

第6章 子宮筋腫治療薬の世界市場：タイプ別

  • 市場スナップショット
  • 子宮筋腫治療薬の世界市場：タイプ別、実績 - ポテンシャル分析
  • 子宮筋腫治療薬の世界市場：タイプ別推定・予測（2020-2030年）
  • 子宮筋腫治療薬の世界市場、サブセグメント別分析
    • 漿膜下筋腫
    • 硬膜内子宮筋腫
    • 粘膜下筋腫
    • 血腫型子宮筋腫

第7章 子宮筋腫治療薬の世界市場：エンドユーザー別

  • 市場スナップショット
  • 子宮筋腫治療薬の世界市場：エンドユーザー別、実績 - ポテンシャル分析
  • 子宮筋腫治療薬の世界市場：エンドユーザー別推定・予測（2020-2030年）
  • 子宮筋腫治療薬の世界市場、サブセグメント別分析
    • 病院
    • 小売薬局
    • その他

第8章 子宮筋腫治療薬の世界市場・地域別分析

  • 主要国
  • 主な新興国
  • 子宮筋腫治療薬市場、地域別市場スナップショット
  • 北米
    • 米国
      • 薬剤クラスの推定・予測、2020-2030年
      • タイプの推定・予測、2020-2030年
      • エンドユーザーの推定・予測、2020～2030年
    • カナダ
  • 欧州の子宮筋腫治療薬市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋子宮筋腫治療薬市場スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカの子宮筋腫治療薬市場スナップショット
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • その他中東とアフリカ

第9章 競合情報

  • 主要企業のSWOT分析
  • 主要市場戦略
  • 企業プロファイル
    • Myovant Sciences Gmbh
      • 主要情報
      • 概要
      • 財務（データの入手可能性によります）
      • 製品概要
      • 最近の動向
    • Pfizer Inc.
    • Abbvie Inc.
    • Ferring B.v
    • AstraZeneca
    • Bayer AG
    • Amring Pharmaceuticals Inc.
    • Watson Pharma Inc.
    • Boston scientific corporation
    • Gynesonics Inc.

第10章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • 検証
    • 出版
  • 調査属性
  • 調査前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Uterine fibroid treatment drugs Market, report scope
  • TABLE 2. Global Uterine fibroid treatment drugs Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Uterine fibroid treatment drugs Market estimates & forecasts by Drug Class 2020-2030 (USD Billion)
  • TABLE 4. Global Uterine fibroid treatment drugs Market estimates & forecasts by Type 2020-2030 (USD Billion)
  • TABLE 5. Global Uterine fibroid treatment drugs Market estimates & forecasts by End User 2020-2030 (USD Billion)
  • TABLE 6. Global Uterine fibroid treatment drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 7. Global Uterine fibroid treatment drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global Uterine fibroid treatment drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global Uterine fibroid treatment drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Uterine fibroid treatment drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Uterine fibroid treatment drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Uterine fibroid treatment drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Uterine fibroid treatment drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. Global Uterine fibroid treatment drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. Global Uterine fibroid treatment drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16. U.S. Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 17. U.S. Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 18. U.S. Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 19. Canada Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 20. Canada Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 21. Canada Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22. UK Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 23. UK Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 24. UK Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25. Germany Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 26. Germany Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 27. Germany Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28. France Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 29. France Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 30. France Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31. Italy Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 32. Italy Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 33. Italy Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34. Spain Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 35. Spain Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 36. Spain Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37. RoE Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 38. RoE Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 39. RoE Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40. China Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 41. China Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 42. China Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43. India Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 44. India Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 45. India Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46. Japan Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 47. Japan Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 48. Japan Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49. South Korea Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 50. South Korea Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 51. South Korea Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52. Australia Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 53. Australia Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 54. Australia Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55. RoAPAC Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 56. RoAPAC Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 57. RoAPAC Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58. Brazil Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 59. Brazil Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 60. Brazil Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61. Mexico Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 62. Mexico Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 63. Mexico Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64. RoLA Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 65. RoLA Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 66. RoLA Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67. Saudi Arabia Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 68. South Africa Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 69. RoMEA Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 70. List of secondary sources, used in the study of global Uterine fibroid treatment drugs Market
  • TABLE 71. List of primary sources, used in the study of global Uterine fibroid treatment drugs Market
  • TABLE 72. Years considered for the study
  • TABLE 73. Exchange rates considered

List of tables and figures are dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

  • FIG 1. Global Uterine fibroid treatment drugs Market, research methodology
  • FIG 2. Global Uterine fibroid treatment drugs Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Uterine fibroid treatment drugs Market, key trends 2022
  • FIG 5. Global Uterine fibroid treatment drugs Market, growth prospects 2023-2030
  • FIG 6. Global Uterine fibroid treatment drugs Market, porters 5 force model
  • FIG 7. Global Uterine fibroid treatment drugs Market, pest analysis
  • FIG 8. Global Uterine fibroid treatment drugs Market, value chain analysis
  • FIG 9. Global Uterine fibroid treatment drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Uterine fibroid treatment drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Uterine fibroid treatment drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Uterine fibroid treatment drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Uterine fibroid treatment drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Uterine fibroid treatment drugs Market, regional snapshot 2020 & 2030
  • FIG 15. North America Uterine fibroid treatment drugs Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Uterine fibroid treatment drugs Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific Uterine fibroid treatment drugs Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Uterine fibroid treatment drugs Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Uterine fibroid treatment drugs Market 2020 & 2030 (USD Billion)

List of tables and figures are dummy in nature, final lists may vary in the final deliverable

目次

Global Uterine Fibroid Treatment Drugs Market is valued at approximately USD 1.80 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 10.2% over the forecast period 2023-2030. The Uterine Fibroid Treatment Drugs are specifically developed to treat uterine fibroid, which are benign tumors that grow in the uterus. This is a common noncancerous condition affecting the uterus in women of reproductive age. The Uterine Fibroid Treatment Drugs market is being driven by factors such as the increasing number of new product launches and the rising prevalence of uterine fibroids.

These drugs include GnRH agonists, progestin-releasing IUDs, SPRMs, NSAIDs, and tranexamic acid, which aim to reduce fibroid size, manage symptoms such as heavy bleeding and pain, or both. On June 2022, Yselty, an oral GnRH antagonist was authorized by the EMA for the treatment of moderate to severe symptoms of uterine leiomyomas. GnRH antagonist, Myfembree, was authorised by the U.S. FDA for the treatment of heavy bleeding associated with uterine fibroids. along with that on May 2021, Myovant Sciences and Pfizer obtained U.S. FDA approval for Myfembree (relugolix), a medication specifically indicated for the treatment of heavy bleeding associated with uterine fibroids. The effectiveness of these newly launched drugs creates the growth of the market. In addition, the Growing awareness among women about uterine fibroids treatment and various governments working on early fibroids detection and treatment may create lucrative opportunities in the market. However, the high cost of fibroid treatment drugs is hindering the growth of the market.

The key regions considered for the Global Uterine Fibroid Treatment Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rising prevalence of uterine fibroids, increasing case of pregnancy complications due to fibroids, and approval of novel treatment options. Asia Pacific is considered the fastest-growing region during the forecasted period due to the presence of two massively populated countries such as India and China. Global companies are entering into agreement with local player for the development and commercialization of therapies in the region.

Major market player included in this report are:

  • Myovant Sciences GmbH
  • Pfizer Inc.
  • Abbvie, Inc.
  • Ferring B.V.
  • AstraZeneca
  • Bayer AG
  • Amring Pharmaceuticals Inc.
  • Watson Pharma, Inc.
  • Boston scientific corporation
  • Gynesonics Inc.

Recent Developments in the Market:

  • On May 2021, Myovant Sciences and Pfizer Inc. announces that the United States Food and Drug Administration (FDA) had approved MYFEMBREE, the first regular or Myfembree (relugolix) is an FDA-approved, once-daily treatment designed to manage heavy menstrual bleeding in premenopausal women with uterine fibroids, and it can be used for up to 24 months.
  • On February 2021, Pfizer and Myovant release favorable results from the Phase III LIBERTY 1 and LIBERTY 2 investigations. In women with uterine fibroids, the companies are testing a once-daily combination treatment of relugolix plus estradiol and norethindrone acetate.

Global Uterine Fibroid Treatment Drugs Market Report Scope:

  • Historical Data: 2020 - 2021
  • Base Year for Estimation: 2022
  • Forecast period: 2023-2030
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Drug class, Type, End user, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Drug class:

  • Gonadotropin-releasing Hormone (GnRH) Agonists
  • Gonadotropin-releasing Hormone (GnRH) Antagonists
  • Progestin-releasing Intrauterine Device (IUD) & Contraceptives
  • Non-hormonal Medications
  • Others

By Type:

  • Subserosal Fibroids
  • Intramural Fibroids
  • Submucosal Fibroids
  • Pedunculated Fibroids

By End user:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Other

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Uterine fibroid treatment drugs Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Uterine fibroid treatment drugs Market, by Drug Class, 2020-2030 (USD Billion)
    • 1.2.3. Uterine fibroid treatment drugs Market, by Type, 2020-2030 (USD Billion)
    • 1.2.4. Uterine fibroid treatment drugs Market, by End User, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Uterine fibroid treatment drugs Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Uterine fibroid treatment drugs Market Dynamics

  • 3.1. Uterine fibroid treatment drugs Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing number of new product launches
      • 3.1.1.2. Rising prevalence of uterine fibroid
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Uterine fibroid treatment drugs
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Growing awareness of uterine fibroid in women
      • 3.1.3.2. Government focus on early detection of uterine and treatment

Chapter 4. Global Uterine fibroid treatment drugs Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Uterine fibroid treatment drugs Market, by Drug Class

  • 5.1. Market Snapshot
  • 5.2. Global Uterine fibroid treatment drugs Market by Drug Class, Performance - Potential Analysis
  • 5.3. Global Uterine fibroid treatment drugs Market Estimates & Forecasts by Drug Class 2020-2030 (USD Billion)
  • 5.4. Uterine fibroid treatment drugs Market, Sub Segment Analysis
    • 5.4.1. Gonadotropin-releasing Hormone (GnRH) Agonists
    • 5.4.2. Gonadotropin-releasing Hormone (GnRH) Antagonists
    • 5.4.3. Progestin-releasing Intrauterine Device (IUD) & Contraceptives
    • 5.4.4. Non-hormonal Medications
    • 5.4.5. Others

Chapter 6. Global Uterine fibroid treatment drugs Market, by Type

  • 6.1. Market Snapshot
  • 6.2. Global Uterine fibroid treatment drugs Market by Type, Performance - Potential Analysis
  • 6.3. Global Uterine fibroid treatment drugs Market Estimates & Forecasts by Type 2020-2030 (USD Billion)
  • 6.4. Uterine fibroid treatment drugs Market, Sub Segment Analysis
    • 6.4.1. Subserosal Fibroids
    • 6.4.2. Intramural Fibroids
    • 6.4.3. Submucosal Fibroids
    • 6.4.4. Pedunculated Fibroids

Chapter 7. Global Uterine fibroid treatment drugs Market, by End User

  • 7.1. Market Snapshot
  • 7.2. Global Uterine fibroid treatment drugs Market by End User, Performance - Potential Analysis
  • 7.3. Global Uterine fibroid treatment drugs Market Estimates & Forecasts by End User 2020-2030 (USD Billion)
  • 7.4. Uterine fibroid treatment drugs Market, Sub Segment Analysis
    • 7.4.1. Hospitals
    • 7.4.2. Retail pharmacies
    • 7.4.3. Other

Chapter 8. Global Uterine fibroid treatment drugs Market, Regional Analysis

  • 8.1. Top Leading Countries
  • 8.2. Top Emerging Countries
  • 8.3. Uterine fibroid treatment drugs Market, Regional Market Snapshot
  • 8.4. North America Uterine fibroid treatment drugs Market
    • 8.4.1. U.S. Uterine fibroid treatment drugs Market
      • 8.4.1.1. Drug Class breakdown estimates & forecasts, 2020-2030
      • 8.4.1.2. Type breakdown estimates & forecasts, 2020-2030
      • 8.4.1.3. End User breakdown estimates & forecasts, 2020-2030
    • 8.4.2. Canada Uterine fibroid treatment drugs Market
  • 8.5. Europe Uterine fibroid treatment drugs Market Snapshot
    • 8.5.1. U.K. Uterine fibroid treatment drugs Market
    • 8.5.2. Germany Uterine fibroid treatment drugs Market
    • 8.5.3. France Uterine fibroid treatment drugs Market
    • 8.5.4. Spain Uterine fibroid treatment drugs Market
    • 8.5.5. Italy Uterine fibroid treatment drugs Market
    • 8.5.6. Rest of Europe Uterine fibroid treatment drugs Market
  • 8.6. Asia-Pacific Uterine fibroid treatment drugs Market Snapshot
    • 8.6.1. China Uterine fibroid treatment drugs Market
    • 8.6.2. India Uterine fibroid treatment drugs Market
    • 8.6.3. Japan Uterine fibroid treatment drugs Market
    • 8.6.4. Australia Uterine fibroid treatment drugs Market
    • 8.6.5. South Korea Uterine fibroid treatment drugs Market
    • 8.6.6. Rest of Asia Pacific Uterine fibroid treatment drugs Market
  • 8.7. Latin America Uterine fibroid treatment drugs Market Snapshot
    • 8.7.1. Brazil Uterine fibroid treatment drugs Market
    • 8.7.2. Mexico Uterine fibroid treatment drugs Market
  • 8.8. Middle East & Africa Uterine fibroid treatment drugs Market
    • 8.8.1. Saudi Arabia Uterine fibroid treatment drugs Market
    • 8.8.2. South Africa Uterine fibroid treatment drugs Market
    • 8.8.3. Rest of Middle East & Africa Uterine fibroid treatment drugs Market

Chapter 9. Competitive Intelligence

  • 9.1. Key Company SWOT Analysis
    • 9.1.1. Company 1
    • 9.1.2. Company 2
    • 9.1.3. Company 3
  • 9.2. Top Market Strategies
  • 9.3. Company Profiles
    • 9.3.1. Myovant Sciences Gmbh
      • 9.3.1.1. Key Information
      • 9.3.1.2. Overview
      • 9.3.1.3. Financial (Subject to Data Availability)
      • 9.3.1.4. Product Summary
      • 9.3.1.5. Recent Developments
    • 9.3.2. Pfizer Inc.
    • 9.3.3. Abbvie Inc.
    • 9.3.4. Ferring B.v
    • 9.3.5. AstraZeneca
    • 9.3.6. Bayer AG
    • 9.3.7. Amring Pharmaceuticals Inc.
    • 9.3.8. Watson Pharma Inc.
    • 9.3.9. Boston scientific corporation
    • 9.3.10. Gynesonics Inc.

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption